JP2005523269A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523269A5
JP2005523269A5 JP2003565465A JP2003565465A JP2005523269A5 JP 2005523269 A5 JP2005523269 A5 JP 2005523269A5 JP 2003565465 A JP2003565465 A JP 2003565465A JP 2003565465 A JP2003565465 A JP 2003565465A JP 2005523269 A5 JP2005523269 A5 JP 2005523269A5
Authority
JP
Japan
Prior art keywords
acid
pharmaceutical composition
pharmaceutically acceptable
carnitine
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IT2003/000023 external-priority patent/WO2003066041A1/en
Publication of JP2005523269A publication Critical patent/JP2005523269A/ja
Publication of JP2005523269A5 publication Critical patent/JP2005523269A5/ja
Pending legal-status Critical Current

Links

JP2003565465A 2002-02-07 2003-01-23 老人性うつ病の治療におけるカルニチン Pending JP2005523269A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35432302P 2002-02-07 2002-02-07
PCT/IT2003/000023 WO2003066041A1 (en) 2002-02-07 2003-01-23 Carnitine in the treatment of geriatric depression

Publications (2)

Publication Number Publication Date
JP2005523269A JP2005523269A (ja) 2005-08-04
JP2005523269A5 true JP2005523269A5 (enExample) 2006-03-09

Family

ID=27734357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565465A Pending JP2005523269A (ja) 2002-02-07 2003-01-23 老人性うつ病の治療におけるカルニチン

Country Status (10)

Country Link
US (1) US20040009926A1 (enExample)
EP (1) EP1471904A1 (enExample)
JP (1) JP2005523269A (enExample)
KR (1) KR20040083471A (enExample)
AR (1) AR038350A1 (enExample)
AU (1) AU2003219511A1 (enExample)
CA (1) CA2469925A1 (enExample)
MX (1) MXPA04007506A (enExample)
PL (1) PL374082A1 (enExample)
WO (1) WO2003066041A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
EP1641806B1 (en) 2003-05-29 2009-07-29 Jay W. Pettegrew Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders
PT2582368T (pt) 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
CA2964971C (en) 2014-10-28 2023-04-11 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
US11918336B2 (en) * 2019-02-19 2024-03-05 King Abdullah University Of Science And Technology Reduced feature generation for signal classification based on position weight matrix
EP4149437A1 (en) 2020-05-15 2023-03-22 Alfasigma S.p.A. Composition comprising methylfolate
CA3238205A1 (en) * 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5879884A (en) * 1994-12-29 1999-03-09 Peroutka; Stephen J. Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394
JP3425276B2 (ja) * 1995-08-11 2003-07-14 株式会社日立製作所 情報通知システム
JPH10143640A (ja) * 1996-11-15 1998-05-29 Nippon Lsi Card Kk 携帯コンピュータ及びそれを用いた情報管理システム並びにそれを用いた立体地図の作成方法
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism

Similar Documents

Publication Publication Date Title
JP2021120379A5 (enExample)
JP2011510075A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP5085541B2 (ja) 疲労軽減剤
JP2005523269A5 (enExample)
AU2010202396A1 (en) Use of L-carnitine for the treatment of cardiovascular diseases
JP3942207B2 (ja) うつ性症状改善剤
US20070197647A1 (en) Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients
JP2004182705A (ja) ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US20180140570A1 (en) Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof
TW200534852A (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP2009512430A5 (enExample)
KR970073581A (ko) 초로기성 알쯔하이머 질환 치료용 카르니틴 유도체 함유 의약품
JP2004532866A5 (enExample)
JP2003522782A5 (enExample)
CA2448244A1 (en) Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
HU229214B1 (hu) Propionil-L-karnitint és további hatóanyagokat tartalmazó kombinációs készítmény alkalmazása merevedési zavar kezelésére
CA2507429A1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
PT1174131E (pt) Utilização de um agente que melhora a função dos astrocitos para o tratamento da doença de parkinson
JP2006523685A5 (enExample)
JP2008505134A5 (enExample)
JP2006511531A5 (enExample)
JP2008539191A5 (enExample)
JP2008534433A5 (enExample)
JP2008517872A5 (enExample)